Deepak Nitrite Ltd (DEEPAKNTR)

Deepak Nitrite Receives Rs 127 Crore Insurance Settlement - 25 Apr, 2024

Deepak Nitrite has received a final insurance settlement of Rs 127 crore for the fire incident that occurred at its Nandesari Plant in June 2022, covering damage to properties, plant, equipment, inventory, and loss of profit due to business interruption.

Deepak Nitrite's ROCE Trend Impresses Analysts - 15 Apr, 2024

Deepak Nitrite's Return on Capital Employed (ROCE) has grown considerably to 23% in the last five years, making it a potential multi-bagger. The company is effectively making more money per dollar of capital used, and its worth noting that the amount of capital has increased too by 155%. This improvement in ROCE has come from the business underlying economics, which is great to see.

Deepak Nitrite Ltd Stock Shows Strong Breakout Above Trendline Resistance - 11 Apr, 2024

The Deepak Nitrite Ltd stock has broken above its trendline resistance at 2,260 with significant momentum and high volume. The current market price is at 2,297, making it a promising buy opportunity with potential targets set at 2,400 and above.

Deepak Nitrite Q4 Revenue Likely to Remain Flat - 08 Apr, 2024

Deepak Nitrite's Q4 revenue is expected to remain flat QoQ due to seasonally higher numbers for the standalone business, down YoY on subdued demand recovery in end-use industries. EBITDA margin may fall 269 bps to 15% on lower spreads in phenolics business.

Deepak Nitrite Among F&O Stocks with Positive Returns in April - 01 Apr, 2024

According to reports, Deepak Nitrite is among the F&O stocks that have closed positively for nine or more times in the last 10 Aprils. The average returns for these stocks stood at over 5%. No specific information on Deepak Nitrite's performance was provided.

Deepak Nitrite's Backward Integration May Not Renew Investor Interest - 28 Mar, 2024

Specialty chemicals company Deepak Nitrite has started operations at its fluorination plant in Dahej, investing ₹200 crore to reduce dependence on benzotrifluoride imports from China. However, the financial impact is modest and may not renew investor interest. The company's earnings growth is more correlated with capital expenditure-led volume growth rather than margin-led growth through pricing power. Its expansion plan entails investment of nearly ₹15,000 crore over five years for import substitution opportunities. The lack of pricing power could lead to a collapse in P/E multiple.